NDAINJECTIONINJECTABLE
Approved
Nov 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NICARDIPINE HYDROCHLORIDE (nicardipine hydrochloride) by Fosun Pharma is mechanism of action nicardipine hydrochloride capsules are a calcium entry blocker (slow channel blocker or calcium ion antagonist) that inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle without changing serum calcium concentrations. First approved in 2009.
Drug data last refreshed 8h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Nicardipine hydrochloride is an injectable calcium channel blocker approved in 2009 for cardiovascular system disease management. It selectively inhibits calcium ion influx into vascular smooth muscle, producing vasodilation with minimal cardiac effects. The injectable formulation enables rapid hypertension control in acute clinical settings.
LOE Approaching
Product approaching loss of exclusivity with limited linked job postings, indicating a contracting team and reduced commercial investment.
Mechanism of Action
Mechanism of Action Nicardipine hydrochloride capsules are a calcium entry blocker (slow channel blocker or calcium ion antagonist) that inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle without changing serum calcium concentrations. The contractile processes…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on nicardipine hydrochloride offers limited growth opportunity due to LOE-approaching status and zero linked job postings; best suited for professionals seeking stability in a mature, established cardiovascular franchise or roles transitioning to generic defense and operational efficiency. Career trajectory is likely consolidation-focused rather than expansion-driven.
Worked on NICARDIPINE HYDROCHLORIDE at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.